Finance

Lists
Why is MMED down 2.20%?
Dive Deeper
MMED:NASDAQ
MiniMed Group Inc
$20.04
-2.20%
(-0.45) 1D
$20.04
0.00% (0.00)
After hours
Closed: Sep 29, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MMED...
Open
$20.31
High
$20.36
Low
$19.73
Mkt. cap
5.64B
Avg. vol.
2.39M
Volume
0.00
52-wk high
$24.43
52-wk low
$10.65
No. of employees
8K
Open
$20.31
High
$20.36
Low
$19.73
Mkt. cap
5.64B
Avg. vol.
2.39M
Volume
0.00
52-wk high
$24.43
52-wk low
$10.65
No. of employees
8K
News stories
From web sources and news partners
About MiniMed Group Inc
CEO-
Employees8K
Founded1983
Headquarters-
SectorMedical device
Websiteminimed.com
Analyst ratings
Based on 11 analysts giving stock ratings to MMED in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for MMED in the last 3 months.
Highest
Current $20.04
$29.00 (+44.71%)
Average
$26.40 (+31.74%)
Lowest
$21.00 (+4.79%)
Analyst
Recommendation
Action
Price target
Projected
Date
Richard Newitter
Truist Financial
Buy
Initiated
$29.00
+44.7%
09/24/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
$21.00
+4.8%
09/18/2026
Steven Lichtman
William Blair
Buy
Maintained
-
-
09/14/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
$26.00
+29.7%
09/08/2026
Pito Chickering
Deutsche Bank
Buy
Reiterated
$25.00
+24.8%
09/02/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
$27.00
+34.7%
09/02/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$26.00
+29.7%
09/02/2026
Patrick Wood
UBS
Buy
Maintained
$28.00
+39.7%
09/02/2026
Marie Thibault
BTIG
Buy
Reiterated
$28.00
+39.7%
09/01/2026
Joanne Wuensch
Citi
Buy
Reiterated
$26.00
+29.7%
09/02/2026
Travis Steed
Bank of America Securities
Buy
Reiterated
$28.00
+39.7%
09/01/2026
Unknown Analyst
UBS
Buy
Initiated
$25.00
+24.8%
07/28/2026
Matthew O'Brien
Piper Sandler
Hold
Reiterated
$16.00
-20.2%
06/04/2026
David Roman
Goldman Sachs
Buy
Maintained
$24.00
+19.8%
06/03/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
$20.00
-0.2%
06/03/2026
Matt Miksic
Barclays
Buy
Initiated
$26.00
+29.7%
03/31/2026
Unknown Analyst
Morgan Stanley
Buy
Initiated
$19.00
-5.2%
03/31/2026
Last report
Sep 1, 2026
Fiscal period
Q1 2027
EPS / Est. (USD)
$0.13 / $0.10
+37.76%beat
Revenue / Est. (USD)
843.00M / 828.43M
+1.76%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Jul 2025
Jan 2026
Apr 2026
Jul 2026
Revenue
723.00M
790.00M
837.00M
843.00M
Cost of goods sold
314.00M
422.00M
357.00M
378.00M
Cost of revenue
314.00M
422.00M
357.00M
378.00M
Research and development expenses
125.00M
114.00M
99.00M
115.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
283.00M
309.00M
299.00M
312.00M
Operating expense
406.00M
455.00M
410.00M
463.00M
Total operating expenses
720.00M
877.00M
767.00M
841.00M
Operating income
3.00M
-87.00M
70.00M
2.00M
Other non operating income
1.00M
1.00M
1.00M
-
EBT including unusual items
-13.00M
-99.00M
-92.00M
4.00M
EBT excluding unusual items
4.00M
-86.00M
71.00M
2.00M
Income tax expense
3.00M
12.00M
93.00M
4.00M
Effective tax rate
-23.08%
-12.12%
-101.09%
100.00%
Other operating expenses
-2.00M
32.00M
12.00M
36.00M
Net income
-19.00M
-119.00M
-185.00M
-
Net profit margin
-2.63%
-15.06%
-22.10%
-
Earnings per share
-
0.08
-0.60
0.13
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
38.75M
-48.00M
109.00M
41.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps